Evidence map›Paper›PMID 35212794›Full record

ArticleJournal of mathematical biology2022

A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis.

Souvik Roy, Zui Pan, Suvra Pal

Abstract read
In one paragraph

Article in Journal of mathematical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. A Fokker-Planck framework for control of epidemics.Journal of mathematical biology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Souvik RoyDepartment of Mathematics, The University of Texas at Arlington, Arlington, TX, 76019-0407, USA. souvik.roy@uta.edu.ORCID 0000-0002-6134-1381
Zui PanCollege of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX, 76019-0407, USA.
Suvra PalDepartment of Mathematics, The University of Texas at Arlington, Arlington, TX, 76019-0407, USA.ORCID 0000-0001-9864-9489

Funding

Oncogenic Function of Ca2+ Channel Orai1 in Esophageal CarcinogenesisR01CA185055 · NCI · OHIO STATE UNIVERSITY · PI CHEN, TONG, PAN, ZUI · 2015 to 2019
$1.6M
Data-driven QSP software for personalized colon cancer treatmentR21CA242933 · NCI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI PAL, SUVRA, ROY, SOUVIK · 2019 to 2020
$547k
NCI NIH HHS R01 CA185055NCI NIH HHS R21 CA242933NCI NIH HHS R21CA242933NIH HHS R01 CA185055
6 · The paper itself

Abstract

In this paper, a new framework for obtaining personalized optimal treatment strategies in colon cancer-induced angiogenesis is presented. The dynamics of colon cancer is given by a Itó stochastic process, which helps in modeling the randomness present in the system. The stochastic dynamics is then represented by the Fokker-Planck (FP) partial differential equation that governs the evolution of the associated probability density function. The optimal therapies are obtained using a three step procedure. First, a finite dimensional FP-constrained optimization problem is formulated that takes input individual noisy patient data, and is solved to obtain the unknown parameters corresponding to the individual tumor characteristics. Next, a sensitivity analysis of the optimal parameter set is used to determine the parameters to be controlled, thus, helping in assessing the types of treatment therapies. Finally, a feedback FP control problem is solved to determine the optimal combination therapies. Numerical results with the combination drug, comprising of Bevacizumab and Capecitabine, demonstrate the efficiency of the proposed framework.

Indexed as

Colonic NeoplasmsFeedbackHumansStochastic ProcessesAnti-angiogenic drugsChemotherapyFokker–Planck optimizationNon-linear conjugate gradientWeibull distribution

Identifiers

PMID35212794
PMCPMC8903165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.